You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

405 Results
Guidelines and Advice
Mar 2019
Blog post
Jane Smart, Senior Specialist, Technical Training, Legal and Privacy, CCO, shares her unique perspectives of cancer as a patient and as a parent....
Apr 2019
Blog post
Anyone who has lived with a diagnosis of cancer or has supported a loved one through treatment knows the toll that the illness can carry. Travelling...
Apr 2019
Document
Document
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Nov 2024
Document
Document

Pages